ENG/中
美国
老虎證券
行情
产品介绍
Cash Boost账户
美股
美股碎股
港股
A股通
期权
期货
美国国债
定投
固定票息票据
Tiger BOSS Debit Card
基金超市
老虎钱袋子
老虎API平台
Wealth
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
专栏
TigerGPT
机构
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務
亞盛醫藥
20.11
+1.41
7.54%
成交量:
1.44萬
成交額:
28.55萬
市值:
17.51億
市盈率:
-27.34
高:
20.11
開:
19.33
低:
19.32
收:
18.70
資料載入中...
總覽
公司
新聞
公告
異動解讀 | 亞盛醫藥財報亮眼,盤中大漲6.44%
异动解读
·
03-28
異動解讀 | 亞盛醫藥盤中大漲6.44%,年度營收暴增342%引發投資者熱情
异动解读
·
03-28
拳頭產品國內銷售大增52%,亞盛醫藥去年虧損收窄,欲挑戰艾伯維血液腫瘤明星藥
时代财经
·
03-28
亞盛醫藥-B績後漲超8% 公司全年收入同比增長342%
新浪港股
·
03-28
港股異動 | 亞盛醫藥-B(06855)績後再漲9% 耐立克銷售額顯著增長 公司全年收入增超3.4倍
智通财经
·
03-28
全年營收大增342%背後,亞盛醫藥-B全球創新與商業化全面提速
智通财经
·
03-28
全年營收大增342%背後,亞盛醫藥-B(06855)全球創新與商業化全面提速
智通财经网
·
03-28
異動解讀 | 亞盛醫藥盤中大漲8.76%,2024年收入暴增342%遠超預期
异动解读
·
03-27
亞盛醫藥公佈2024年業績:邁入全球創新新階段
美通社
·
03-27
異動解讀 | 亞盛醫藥盤前大漲8.60%,年度收入暴增342%遠超預期
异动解读
·
03-27
亞盛醫藥2024年度收入9.81億元 同比增長342%
财中社
·
03-27
亞盛醫藥-B(06855)核心產品耐立克銷售同比增長53%,雙引擎驅動打開商業化空間
智通财经
·
03-27
港股異動 | 亞盛醫藥-B(06855)現漲超9% 公司五項臨牀前研究進展入選2025年美國癌症研究協會年會
智通财经
·
03-27
【AACR 2025】亞盛醫藥宣佈將在2025年美國癌症研究協會年會上公佈五項最新臨牀前進展
美通社
·
03-26
【亞盛醫藥-B(06855.HK):五項臨牀前研究進展入選2025年美國癌症研究協會年會】亞盛醫藥-B(06855.HK)發佈公告,公司共有五項臨牀前研究進展入選2025年美國癌症研究協會(AACR)年會。此次會議將於2025年4月25日至2025年4月30日在美國芝加哥舉行。
金融界
·
03-26
亞盛醫藥-B(06855):五項臨牀前研究進展入選2025年美國癌症研究協會年會
智通财经
·
03-26
亞盛醫藥上漲2.35%,報19.14美元/股,總市值16.66億美元
金融界
·
03-14
亞盛醫藥-B早盤漲超5% 耐立克®第三次獲CDE納入突破性治療品種
新浪港股
·
03-07
港股異動 | 亞盛醫藥-B(06855)盤中漲超4% 耐立克®第三次獲CDE納入突破性治療品種
智通财经
·
03-07
亞盛醫藥下跌2.26%,報19.03美元/股,總市值16.57億美元
金融界
·
03-07
更多
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/AAPG/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AAPG","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AAPG\",,,,,undefined,":{"symbol":"AAPG","market":"US","secType":"STK","nameCN":"亞盛醫藥","latestPrice":20.11,"timestamp":1744659158780,"preClose":18.7,"halted":0,"volume":14435,"delay":0,"floatShares":8260100,"shares":87066645,"eps":-0.735552,"marketStatus":"交易中","change":1.41,"latestTime":"04-14 15:35:25 EDT","open":19.33,"high":20.11,"low":19.32,"amount":285526.17655,"amplitude":0.042246,"askPrice":20.6,"askSize":600,"bidPrice":19.66,"bidSize":601,"shortable":3,"etf":0,"ttmEps":-0.735552,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1744660800000},"marketStatusCode":2,"adr":0,"adrRate":4,"listingDate":1737694800000,"exchange":"NASDAQ","adjPreClose":18.7,"preHourTrading":{"tag":"盘前","latestPrice":19.29,"preClose":18.7,"latestTime":"08:37 EDT","volume":200,"amount":3858,"timestamp":1744634247763},"postHourTrading":{"tag":"盘后","latestPrice":18.7,"preClose":18.7,"latestTime":"16:05 EDT","volume":2,"amount":37.1,"timestamp":1744401909242},"volumeRatio":0.182094},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AAPG\",,,,,undefined,":{"symbol":"AAPG","floatShares":8260100,"roa":"-9.25%","roe":"-235.32%","lyrEps":-0.735552,"volumeRatio":0.182094,"shares":87066645,"dividePrice":0,"high":20.11,"amplitude":0.042246,"preClose":18.7,"low":19.32,"week52Low":16.5,"pbRate":"48.43","psRate":"13.05","week52High":24.0204,"institutionHeld":0,"latestPrice":20.11,"committee":0.000833,"eps":-0.735552,"divideRate":0,"volume":14435,"delay":0,"ttmEps":-0.735552,"open":19.33,"prevYearClose":17.25,"prevWeekClose":18.7,"prevMonthClose":21.95,"prevQuarterClose":21.95,"fiveDayClose":20.4,"twentyDayClose":19.68,"sixtyDayClose":17.25},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AAPG\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1176748047","title":"異動解讀 | 亞盛醫藥財報亮眼,盤中大漲6.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=1176748047","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176748047?lang=zh_tw&edition=fundamental","pubTime":"2025-03-28 21:34","pubTimestamp":1743168870,"startTime":"0","endTime":"0","summary":"周五盘中,亚盛医药股价大涨6.44%,引发市场广泛关注。这一显著涨幅主要源于公司日前发布的2024年度财报中披露的亮眼业绩。根据亚盛医药公布的2024年全年业绩报告,公司实现营收9.81亿元人民币,同比大幅增长342%。除了财务表现优异外,亚盛医药在产品开发和商业化方面也取得了显著进展。此外,亚盛医药今年1月成功登陆美国纳斯达克市场,成为2025年美股生物医药第一股,进一步彰显了其全球化战略布局。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AAPG"],"gpt_icon":0},{"id":"1190695404","title":"異動解讀 | 亞盛醫藥盤中大漲6.44%,年度營收暴增342%引發投資者熱情","url":"https://stock-news.laohu8.com/highlight/detail?id=1190695404","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190695404?lang=zh_tw&edition=fundamental","pubTime":"2025-03-28 21:34","pubTimestamp":1743168870,"startTime":"0","endTime":"0","summary":"亚盛医药今日盘中大涨6.44%,引发市场广泛关注。这一显著涨幅主要源于公司近期发布的2024年全年业绩报告,以及其核心产品的强劲表现。根据亚盛医药公布的2024年财报,公司实现营业收入9.81亿元人民币,同比大幅增长342%。除了财务业绩外,亚盛医药在产品开发和商业化方面也取得了重要进展。这些进展不仅巩固了亚盛医药在国内市场的地位,也为其国际化战略奠定了基础,进一步提升了投资者对公司未来发展前景的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 亚盛医药盘中大涨6.44%,年度营收暴增342%引发投资者热情","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AAPG"],"gpt_icon":0},{"id":"2522093572","title":"拳頭產品國內銷售大增52%,亞盛醫藥去年虧損收窄,欲挑戰艾伯維血液腫瘤明星藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2522093572","media":"时代财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522093572?lang=zh_tw&edition=fundamental","pubTime":"2025-03-28 21:10","pubTimestamp":1743167405,"startTime":"0","endTime":"0","summary":"营收的大幅增长主要得益于武田制药的知识产权收入及药品销售增加。目前,耐立克所有获批适应症均已纳入国家医保药品目录。此外,武田制药还决定认购亚盛医药新发行的7500万美元股份,成为公司第二大股东。报告期内,亚盛医药已经收到来自武田制药的1.75亿美元付款。受益于此,截至报告期末,亚盛医药的现金及银行结余同比增长15.3%,达12.61亿元。目前,亚盛医药正在开展十项注册临床研究,其中两项获美国食品药品监督管理局许可。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025032821104094c441b8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025032821104094c441b8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AAPG","06855","BK1574","BK1161"],"gpt_icon":0},{"id":"2522564678","title":"亞盛醫藥-B績後漲超8% 公司全年收入同比增長342%","url":"https://stock-news.laohu8.com/highlight/detail?id=2522564678","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522564678?lang=zh_tw&edition=fundamental","pubTime":"2025-03-28 10:29","pubTimestamp":1743128940,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n 亚盛医药-B(06855)绩后再涨9%,截至发稿,股价上涨8.24%,现报43.35港元,成交额2.15亿港元。\n 亚盛医药公布2024年全年业绩。报告期内,亚盛医药核心产品耐立克展现增长强劲态势,实现销售收入2.41亿元人民币,同比增长52%。亚盛医药2024全年实现收入9.81亿元人民币,较去年同比增长342%,增长主要来源于产品销售收入和对外合作授权收入等。\n\n\n\n海量资讯、精准解读,尽在新浪财经APP\n\n责任编辑:卢昱君","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-03-28/doc-inerenpv1412789.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06855","BK1161","AAPG","BK1574","BK4139"],"gpt_icon":0},{"id":"2522610265","title":"港股異動 | 亞盛醫藥-B(06855)績後再漲9% 耐立克銷售額顯著增長 公司全年收入增超3.4倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2522610265","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522610265?lang=zh_tw&edition=fundamental","pubTime":"2025-03-28 10:20","pubTimestamp":1743128442,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,亚盛医药-B绩后再涨9%,截至发稿,涨8.74%,报43.55港元,成交额2.02亿港元。消息面上,亚盛医药公布2024年全年业绩。报告期内,亚盛医药核心产品耐立克展现增长强劲态势,实现销售收入2.41亿元人民币,同比增长52%。值得注意的是,报告期内,亚盛医药与武田就耐立克达成独家选择权协议,创下截至目前国内小分子肿瘤药领域的最大的对外权益许可。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1269746.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AAPG","BK4139","BK1161","06855","BK1574"],"gpt_icon":0},{"id":"2522552870","title":"全年營收大增342%背後,亞盛醫藥-B全球創新與商業化全面提速","url":"https://stock-news.laohu8.com/highlight/detail?id=2522552870","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522552870?lang=zh_tw&edition=fundamental","pubTime":"2025-03-28 07:55","pubTimestamp":1743119736,"startTime":"0","endTime":"0","summary":"2024年,港股医药板块受外部因素影响出现较大幅度下跌。从亚盛医药最新披露的2024年年报数据来看,报告期内,亚盛医药实现收入人民币9.81亿元,较去年同比大幅增长342%。其中,耐立克当期实现销售收入2.41亿元,同比增长约53%。此外,武田制药还投资7500万美元,溢价25%认购公司股份,成为亚盛医药重要的产业股东。武田积极合作的背后,侧面反映出耐立克巨大的全球商业化潜力。其中,中金公司维持对亚盛医药“跑赢行业”评级,并表示","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503280759489725c2f7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503280759489725c2f7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AAPG","06855"],"gpt_icon":0},{"id":"2522455787","title":"全年營收大增342%背後,亞盛醫藥-B(06855)全球創新與商業化全面提速","url":"https://stock-news.laohu8.com/highlight/detail?id=2522455787","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522455787?lang=zh_tw&edition=fundamental","pubTime":"2025-03-28 07:55","pubTimestamp":1743119700,"startTime":"0","endTime":"0","summary":"2024年,港股医药板块受外部因素影响出现较大幅度下跌。在此背景下,亚盛医药-B股价却在2024年全年股价累涨66.48%,大幅跑赢指数。从亚盛医药最新披露的2024年年报数据来看,报告期内,亚盛医药实现收入人民币9.81亿元,较去年同比大幅增长342%。其中,耐立克当期实现销售收入2.41亿元,同比增长约53%。截至2024年12月末,公司货币资金余额为12.61亿元,同比增长15.3%。其中,中金公司维持对亚盛医药“跑赢行业”评级,并表示,考虑","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-03-28/doc-inerehfs3207158.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["AAPG","06855"],"gpt_icon":0},{"id":"1171813650","title":"異動解讀 | 亞盛醫藥盤中大漲8.76%,2024年收入暴增342%遠超預期","url":"https://stock-news.laohu8.com/highlight/detail?id=1171813650","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171813650?lang=zh_tw&edition=fundamental","pubTime":"2025-03-27 21:52","pubTimestamp":1743083553,"startTime":"0","endTime":"0","summary":"亚盛医药今日盘中大涨8.76%,引起市场广泛关注。这一显著涨幅主要归因于公司刚刚发布的2024年度业绩报告,其中多项数据大幅超出市场预期。根据亚盛医药公布的2024年全年业绩报告,公司实现收入9.81亿元人民币,同比大幅增长342%。这意味着亚盛医药有望推出第二款重磅产品,进入\"双引擎\"驱动的新发展阶段。这些积极因素共同推动了投资者对亚盛医药未来发展前景的信心,从而带动股价上涨。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AAPG"],"gpt_icon":0},{"id":"2522581414","title":"亞盛醫藥公佈2024年業績:邁入全球創新新階段","url":"https://stock-news.laohu8.com/highlight/detail?id=2522581414","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522581414?lang=zh_tw&edition=fundamental","pubTime":"2025-03-27 21:28","pubTimestamp":1743082080,"startTime":"0","endTime":"0","summary":"报告期内,亚盛医药实现收入人民币9.81亿元,较去年同比增长342%,增长主要来源于武田制药的选择权付款和耐立克(奥雷巴替尼)的强劲销售等 2024年耐立克实现销售收入达人民币2.41亿元,同比增长52% 2025年1月,亚盛医药完成在美国纳斯达克的首次公开发售,募资净额达人民币9.67亿元 报告期内,lisaftoclax(APG-2575)在中国的新药上市申请(NDA)获受理,并被纳入优先审评","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4651394_ZH51394_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4139","BK1161","AAPG","06855","BK1574"],"gpt_icon":0},{"id":"1167179150","title":"異動解讀 | 亞盛醫藥盤前大漲8.60%,年度收入暴增342%遠超預期","url":"https://stock-news.laohu8.com/highlight/detail?id=1167179150","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167179150?lang=zh_tw&edition=fundamental","pubTime":"2025-03-27 20:14","pubTimestamp":1743077693,"startTime":"0","endTime":"0","summary":"3月27日盘前,亚盛医药股价大涨8.60%,投资者对公司刚发布的2024年度业绩报告反应积极。根据公告,亚盛医药2024年全年实现收入9.81亿元人民币,同比大幅增长342%,远超市场预期。此外,亚盛医药在产品管线拓展方面也取得重要进展。这意味着亚盛医药有望推出第二款重磅产品,进入\"双引擎\"驱动的新发展阶段。同时,公司于2025年1月成功在美国纳斯达克上市,募集资金9.67亿元人民币,进一步增强了其财务实力和全球化发展潜力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AAPG"],"gpt_icon":0},{"id":"2522585374","title":"亞盛醫藥2024年度收入9.81億元 同比增長342%","url":"https://stock-news.laohu8.com/highlight/detail?id=2522585374","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522585374?lang=zh_tw&edition=fundamental","pubTime":"2025-03-27 19:30","pubTimestamp":1743075032,"startTime":"0","endTime":"0","summary":"3月27日,亚盛医药(06855)发布截至2024年12月31日止年度业绩公告。公司在报告期内实现收入9.81亿元,同比增长342%,主要受益于武田制药的选择权付款及耐立克?(奥雷巴替尼)强劲的销售。耐立克?在中国的销售收入达到2.41亿元,同比增长52%。此外,公司于2025年1月完成在美国纳斯达克的首次公开发售,募资净额1.33亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503273358175958.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"2522737621","title":"亞盛醫藥-B(06855)核心產品耐立克銷售同比增長53%,雙引擎驅動打開商業化空間","url":"https://stock-news.laohu8.com/highlight/detail?id=2522737621","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522737621?lang=zh_tw&edition=fundamental","pubTime":"2025-03-27 19:14","pubTimestamp":1743074098,"startTime":"0","endTime":"0","summary":"报告期内,亚盛医药核心产品耐立克展现增长强劲态势,实现销售收入2.41亿元人民币,同比增长52%。亚盛医药2024全年实现收入9.81亿元人民币,较去年同比增长342%,增长主要来源于产品销售收入和对外合作授权收入等。值得一提的是,报告期内,亚盛医药就耐立克全球权益与武田达成BD,创下截止目前国内小分子肿瘤药领域的最大的对外权益许可的记录,为其将来的全球商业化进程奠定了基础。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1269154.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06855","BK4139","BK1574","AAPG","BK1161"],"gpt_icon":0},{"id":"2522391752","title":"港股異動 | 亞盛醫藥-B(06855)現漲超9% 公司五項臨牀前研究進展入選2025年美國癌症研究協會年會","url":"https://stock-news.laohu8.com/highlight/detail?id=2522391752","media":"智通财经","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522391752?lang=zh_tw&edition=fundamental","pubTime":"2025-03-27 11:18","pubTimestamp":1743045483,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,亚盛医药-B现涨超9%,截至发稿,涨8.56%,报39.95港元,成交额1.54亿港元。消息面上,亚盛医药发布公告,公司共有五项临床前研究进展入选2025年美国癌症研究协会年会。值得注意的是,本月初亚盛医药公告,公司原创1类新药奥雷巴替尼获国家药品监督管理局药品审评中心纳入“突破性治疗品种”名单,用于联合化疗一线治疗新诊断费城染色体阳性(Ph+)急性淋巴细胞白血病患者。据悉,这是耐立克第三次获CDE纳入突破性治疗品种。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1268725.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"港股异动 | 亚盛医药-B(06855)现涨超9% 公司五项临床前研究进展入选2025年美国癌症研究协会年会","news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","BK1161","AAPG","06855","BK1574"],"gpt_icon":0},{"id":"2522891908","title":"【AACR 2025】亞盛醫藥宣佈將在2025年美國癌症研究協會年會上公佈五項最新臨牀前進展","url":"https://stock-news.laohu8.com/highlight/detail?id=2522891908","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522891908?lang=zh_tw&edition=fundamental","pubTime":"2025-03-26 10:03","pubTimestamp":1742954580,"startTime":"0","endTime":"0","summary":"美国马里兰州罗克维尔市和中国苏州2025年3月26日 /美通社/ -- 致力于在血液肿瘤等领域开发创新药物的领先的生物医药企业——亚盛医药今日宣布,公司共有五项临床前研究进展入选2025年美国癌症研究协会年会。此次会议将于 2025 年 4 月 25 日至 30 日在美国芝加哥举行。截至目前,公司4个在研新药共获16项FDA和1项欧盟孤儿药资格认定,2项FDA快速通道资格以及2项FDA儿童罕见病资格认证。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4650125_ZH50125_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4139","BK1161","AAPG","06855","BK1574"],"gpt_icon":0},{"id":"2522830029","title":"【亞盛醫藥-B(06855.HK):五項臨牀前研究進展入選2025年美國癌症研究協會年會】亞盛醫藥-B(06855.HK)發佈公告,公司共有五項臨牀前研究進展入選2025年美國癌症研究協會(AACR)年會。此次會議將於2025年4月25日至2025年4月30日在美國芝加哥舉行。","url":"https://stock-news.laohu8.com/highlight/detail?id=2522830029","media":"金融界","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522830029?lang=zh_tw&edition=fundamental","pubTime":"2025-03-26 07:57","pubTimestamp":1742947052,"startTime":"0","endTime":"0","summary":"亚盛医药-B(06855.HK)发布公告,公司共有五项临床前研究进展入选2025年美国癌症研究协会(AACR)年会。此次会议将于2025年4月25日至2025年4月30日在美国芝加哥举行。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/26075749045535.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4139","BK1161","AAPG","06855","BK1574"],"gpt_icon":0},{"id":"2522304428","title":"亞盛醫藥-B(06855):五項臨牀前研究進展入選2025年美國癌症研究協會年會","url":"https://stock-news.laohu8.com/highlight/detail?id=2522304428","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522304428?lang=zh_tw&edition=fundamental","pubTime":"2025-03-26 07:53","pubTimestamp":1742946802,"startTime":"0","endTime":"0","summary":"智通财经APP讯,亚盛医药-B(06855)发布公告,公司共有五项临床前研究进展入选2025年美国癌症研究协会(AACR)年会。此次会议将于2025年4月25日至2025年4月30日在美国芝加哥举行。本次将要展示的数据涉及公司五个品种,包括:原创1类新药奥雷巴替尼(商品名:耐立克®;研发代号:HQP1351)、Bcl-2抑制剂APG-2575、FAK/ALK/ROS1三联酪氨酸激酶抑制剂APG-2449、胚胎外胚层发育蛋白(EED)抑制剂APG-5918以及IAP拮抗剂AS03157。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1267687.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","06855","BK1574","AAPG","BK1161"],"gpt_icon":0},{"id":"2519386532","title":"亞盛醫藥上漲2.35%,報19.14美元/股,總市值16.66億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2519386532","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519386532?lang=zh_tw&edition=fundamental","pubTime":"2025-03-14 03:05","pubTimestamp":1741892745,"startTime":"0","endTime":"0","summary":"3月14日,亚盛医药盘中上涨2.35%,截至03:05,报19.14美元/股,成交14.16万美元,总市值16.66亿美元。财务数据显示,截至2024年06月30日,亚盛医药收入总额8.24亿人民币,同比增长477.25%;归母净利润1.63亿人民币,同比增长140.51%。目前公司正在中国、美国、澳大利亚及欧洲开展40多项临床试验。截至目前,公司共有4个在研新药获得16项FDA和1项欧盟孤儿药资格认定,2项FDA快速通道资格以及2项FDA儿童罕见病资格认证。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/14030548733326.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"2517147943","title":"亞盛醫藥-B早盤漲超5% 耐立克®第三次獲CDE納入突破性治療品種","url":"https://stock-news.laohu8.com/highlight/detail?id=2517147943","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517147943?lang=zh_tw&edition=fundamental","pubTime":"2025-03-07 10:47","pubTimestamp":1741315620,"startTime":"0","endTime":"0","summary":" 亚盛医药-B早盘上涨5.07%,现报40.45港元,成交额7852.04万港元。 亚盛医药-B发布公告,公司原创1类新药奥雷巴替尼获国家药品监督管理局药品审评中心纳入“突破性治疗品种”名单,用于联合化疗一线治疗新诊断费城染色体阳性(Ph+)急性淋巴细胞白血病患者。 据悉,这是耐立克第三次获CDE纳入突破性治疗品种。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-03-07/doc-inenuuym7106212.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4017","BK1574","CDE","BK4139","BK1161","AAPG","06855"],"gpt_icon":0},{"id":"2517903144","title":"港股異動 | 亞盛醫藥-B(06855)盤中漲超4% 耐立克®第三次獲CDE納入突破性治療品種","url":"https://stock-news.laohu8.com/highlight/detail?id=2517903144","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517903144?lang=zh_tw&edition=fundamental","pubTime":"2025-03-07 10:21","pubTimestamp":1741314098,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,亚盛医药-B盘中涨超4%,截至发稿,涨4.55%,报40.25港元,成交额5269.94万港元。消息面上,亚盛医药-B发布公告,公司原创1类新药奥雷巴替尼获国家药品监督管理局药品审评中心纳入“突破性治疗品种”名单,用于联合化疗一线治疗新诊断费城染色体阳性(Ph+)急性淋巴细胞白血病患者。据悉,这是耐立克第三次获CDE纳入突破性治疗品种。耐立克是亚盛医药原创1类新药,为中国首个获批上市的第三代BCR-ABL抑制剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258906.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4017","BK4139","06855","AAPG","BK1574","BK1161","CDE"],"gpt_icon":0},{"id":"2517919705","title":"亞盛醫藥下跌2.26%,報19.03美元/股,總市值16.57億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517919705","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517919705?lang=zh_tw&edition=fundamental","pubTime":"2025-03-07 04:18","pubTimestamp":1741292291,"startTime":"0","endTime":"0","summary":"3月7日,亚盛医药盘中下跌2.26%,截至04:18,报19.03美元/股,成交30.32万美元,总市值16.57亿美元。财务数据显示,截至2024年06月30日,亚盛医药收入总额8.24亿人民币,同比增长477.25%;归母净利润1.63亿人民币,同比增长140.51%。目前公司正在中国、美国、澳大利亚及欧洲开展40多项临床试验。截至目前,公司共有4个在研新药获得16项FDA和1项欧盟孤儿药资格认定,2项FDA快速通道资格以及2项FDA儿童罕见病资格认证。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/03/07041848578566.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4139","AAPG"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":75,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AAPG\",params:#limit:5,,,undefined,":[{"date":"2025-03-27","symbol":"AAPG","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2024/12","expectedEps":null,"defaultRemindTime":1743062400000,"name":null,"time":"盤前","dateTimestamp":1743048000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AAPG\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AAPG\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":8,"updateTime":1743134400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AAPG\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AAPG","date":"2025-04-11","current":-29.511221,"percent":0.923077,"low":-36.382297,"twenty":-34.370118,"median":-33.010704,"eighty":-30.892818,"high":-26.74375,"avg":-32.69661,"sd":2.274187,"marketCap":1635879540.94},"quantilePoints":[{"date":"2025-01-31","current":-29.751262,"twenty":-29.75286,"median":-29.751983,"eighty":-29.751262,"marketCap":1478269659.08},{"date":"2025-02-07","current":-32.664532,"twenty":-32.365221,"median":-31.242401,"eighty":-29.752127,"marketCap":1614694688.16},{"date":"2025-02-14","current":-31.1828,"twenty":-32.258438,"median":-31.212601,"eighty":-29.752938,"marketCap":1540476496.81},{"date":"2025-02-21","current":-36.382297,"twenty":-32.721933,"median":-31.802125,"eighty":-29.819279,"marketCap":1806628873.73},{"date":"2025-02-28","current":-33.43308,"twenty":-34.468465,"median":-32.375664,"eighty":-30.230932,"marketCap":1654638501.56},{"date":"2025-03-07","current":-34.452224,"twenty":-34.328072,"median":-32.712367,"eighty":-30.892818,"marketCap":1712841480.27},{"date":"2025-03-14","current":-33.065652,"twenty":-34.096417,"median":-32.760201,"eighty":-31.20664,"marketCap":1644428002.08},{"date":"2025-03-21","current":-32.72391,"twenty":-34.124503,"median":-32.947597,"eighty":-31.448698,"marketCap":1626713850.02},{"date":"2025-03-28","current":-33.955809,"twenty":-34.124503,"median":-33.010704,"eighty":-31.793328,"marketCap":1894714451.86},{"date":"2025-04-04","current":-35.921968,"twenty":-34.855052,"median":-33.21342,"eighty":-31.979778,"marketCap":2000185586.04},{"date":"2025-04-11","current":-29.511221,"twenty":-34.370118,"median":-33.010704,"eighty":-30.892818,"marketCap":1635879540.94}],"updateTime":1744659325686}}}